Overview

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This is a prospective, randomised, open-label, positive-controlled study to investigate the efficacy and safety of Osimertinib plus Carboplatin/Pemetrexed versus Osimertinib monotherapy in metastatic EGFRm NSCLC patients with EGFRm persistence in ctDNA at 3 weeks after first-line therapy with Osimertinib.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Cancer Prevention & Treatment Society

Collaborator:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Treatments:

Carboplatin
Osimertinib
Pemetrexed